Voyager Therapeutics: Promising Alzheimer’s Program and Strong Financial Position Support Buy Rating
Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on VYGR stock, giving a Buy rating yesterday.
Repligen’s Robust Growth and Market Position Drive Buy Rating with $200 Price Target
Analyst Puneet Souda from Leerink Partners maintained a Buy rating on Repligen (RGEN – Research Report) and keeping the price target at ...